Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

Core Insights - Monopar Therapeutics Inc. announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the AASLD – The Liver Meeting 2025, scheduled for November 7-11, 2025 in Washington, D.C. [1] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [3] - The company is also working on Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for treating advanced cancers [3] Presentation Details - The abstract for the oral presentation is available on the conference website, with materials to be accessible on Monopar's website on November 9, 2025 [2] - The presentation will take place on November 9, 2025, from 9:00-9:15 am EST, featuring the presenting author Aftab Ala, MBBS, M.D., FRCP, Ph.D. [5]